# US 2010/0167348 A1 · Peptide capable of binding to immunoglobulin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167348 A1
- Document ID: US20100167348A1
- Status: Published application
- Kind: A1
- Application number: 12/733,288
- Filed: 2008-08-20
- Published: 2010-07-01
- Earliest claimed: 2007-08-21
- Assignees: Takahiro Ochi; Tegene Tiss Inc.; Mmt SA
- Inventors: Takahiro Ochi; Toshikazu Shiba; Osamu Masaki
- Web page: https://patentgrep.com/patent/US20100167348A1

## CPC

- C07K 14/47: from mammals
- A61P 13/12: of the kidneys
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/472: {Complement proteins, e.g. anaphylatoxin, C3a, C5a}
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are: a peptide capable of binding to an immunoglobulin; a fusion protein of the peptide; nucleic acids encoding the peptide and the fusion protein, respectively; production methods for the peptide and the fusion protein, respectively; a composition and a means for binding an immunoglobulin; a pharmaceutical composition for the treatment or prevention of a disease induced by the binding between C1q and an immunoglobulin, which comprises a peptide capable of binding to the immunoglobulin or a fusion protein of the peptide; and others.

## Claims

### Claim 1

A peptide capable of binding to an immunoglobulin, selected from the group consisting of:
(a) a peptide having any of the amino acid sequences of SEQ ID NO: 1 to 7;
(b) a peptide having an amino acid sequence resulting from the deletion, substitution or addition of one or several amino acids in any of the amino acid sequences of SEQ ID NO: 1 to 7; and
(c) a peptide having an amino acid sequence with 66.7% or greater homology to any of the amino acid sequences of SEQ ID NO: 1 to 7.

### Claim 2 (depends on 1)

The peptide according to claim 1, having any of the amino acid sequences of SEQ ID NO: 1 to 7.

### Claim 3 (depends on 1)

The peptide according to claim 1, having the amino acid sequence of SEQ ID NO: 1.

### Claim 4 (depends on 1)

A nucleic acid encoding a peptide capable of binding to an immunoglobulin, selected from the group consisting of:
(a) a nucleic acid encoding the peptide according to claim 1;
(b) a nucleic acid having any of the nucleotide sequences of SEQ ID NO: 8 to 16;
(c) a nucleic acid having a nucleotide sequence resulting from the deletion, substitution or addition of one or several nucleotides in any of the nucleotide sequences of SEQ ID NO: 8 to 16;
(d) a nucleic acid that may hybridize with the nucleic acid of (b) or (c), or the complementary strand thereof under a stringent condition; and
(e) a nucleic acid having a nucleotide sequence with 50% or greater homology to any of the nucleotide sequences of SEQ ID NO: 8 to 16.

### Claim 5 (depends on 4)

The nucleic acid according to claim 4, having any of the nucleotide sequences of SEQ ID NO: 8 to 16.

### Claim 6 (depends on 4)

The nucleic acid according to claim 4, having the nucleotide sequence of SEQ ID NO: 8 or 9.

### Claim 7 (depends on 4)

A vector comprising the nucleic acid according to claim 4.

### Claim 8 (depends on 1)

A fusion protein in which the peptide according to claim 1 is added to the N-terminus and/or C-terminus of a target protein.

### Claim 9 (depends on 8)

A nucleic acid encoding the fusion protein according to claim 8.

### Claim 10 (depends on 9)

A vector comprising the nucleic acid according to claim 9.

### Claim 11 (depends on 4)

A cell comprising the nucleic acid according to claim 4, or a vector comprising the nucleic acid according to claim 4.

### Claim 12 (depends on 7)

A method for producing a peptide capable of binding to an immunoglobulin, comprising the steps of:
(a) transforming a cell with the vector according to claim 7; and
(b) culturing the cell to produce the peptide.

### Claim 13 (depends on 12)

A peptide capable of binding to an immunoglobulin, which can be obtained by the method according to claim 12.

### Claim 14 (depends on 10)

A method for producing a fusion protein in which a peptide capable of binding to an immunoglobulin is added to the N-terminus and/or C-terminus of a target protein, comprising the steps of:
(a) transforming a cell with the vector according to claim 10; and
(b) culturing the cell to produce the fusion protein.

### Claim 15 (depends on 14)

The method according to claim 14, further comprising the step of obtaining the target protein from the fusion protein.

### Claim 16 (depends on 14)

A fusion protein which can be obtained by the method according to claim 14.

### Claim 17 (depends on 1)

A composition for binding an immunoglobulin, comprising the peptide according to claim 1 or a fusion protein in which the peptide according to claim 1 is added to the N-terminus and/or C-terminus of a target protein.

### Claim 18 (depends on 17)

The composition according to claim 17, which is used for determining the presence or the amount of an immunoglobulin, or for isolating an immunoglobulin.

### Claim 19 (depends on 1)

A means for binding an immunoglobulin on which the peptide according to claim 1 or a fusion protein in which the peptide according to claim 1 is added to the N-terminus and/or C-terminus of a target protein is immobilized.

### Claim 20 (depends on 19)

The means according to claim 19, which is used for determining the presence or the amount of an immunoglobulin, or for isolating an immunoglobulin.

### Claim 21 (depends on 1)

A method for binding an immunoglobulin, comprising:
(a) adding to a sample the peptide according to claim 1 or a fusion protein in which a peptide according to claim 1 is added to the N-terminus and/or C-terminus of a target protein; and
(b) checking for a complex of the peptide or fusion protein and an immunoglobulin.

### Claim 22 (depends on 21)

A kit for use in the method according to claim 21, containing a peptide capable of binding to an immunoglobulin or such a fusion protein containing the peptide.

### Claim 23 (depends on 1)

A pharmaceutical composition for the treatment or prevention of a disease induced by the binding between C1q and an immunoglobulin, the pharmaceutical composition comprising the peptide according to claim 1 or a fusion protein in which a peptide according to claim 1 is added to the N-terminus and/or C-terminus of a target protein.

### Claim 24 (depends on 23)

The pharmaceutical composition according to claim 23, wherein the disease is rheumatoid arthritis.

### Claim 25 (depends on 23)

The pharmaceutical composition according to claim 23, wherein the disease is an immune-complex disease such as systemic lupus erythematosus (SLE), glomerulonephritis, vasculitis or arthritis.

### Claim 26 (depends on 1)

The peptide according to claim 1 or a fusion protein in which a peptide according to claim 1 is added to the N-terminus and/or C-terminus of a target protein, which is labeled.

### Claim 27 (depends on 26)

A method for detecting an antibody in a sample, comprising reacting the labeled peptide or fusion protein according to claim 26 with an antibody in the sample, and then detecting the peptide or fusion protein bound to the antibody.
